The corporate healthcare industry is divided over weight-loss drugs. Some of the biggest insurers, such as Aviva and Axa, do not offer weight loss drugs to corporate scheme members, while Bupa and Vitality are now offering programmes that combine weight loss drugs with lifestyle support. The divide on this controversial
and complex new frontier exposes a clear gap in corporate healthcare strategy.
Structural design
With two thirds of UK adults being overweight, a significant proportion of Britain’s workforce faces rising risks of diabetes, cardiovascular disease, sleep apnea, musculoskeletal strain, mental health issues and a host of other conditions accelerated by obesity. According to the Office for Health Improvement & Disparities, obesity is most common among middle-aged adults, with severe cases reducing life expectancy by up to 10 years.
But while weight loss drugs such as Wegovy, Zepboud, Mounjaro and Saxenda offer overweight people a short-cut to losing pounds, they are off the menu for two of the UK’s biggest corporate healthcare providers. Aviva does not cover weight-management medications under its policies and currently has no plans to introduce a funded pathway for them, while Axa Health does not currently provide cover for obesity treatments but continues to review its proposition.
Axa Health commercial director Dr Ali Hasan says: “Axa Health welcomes the positive steps that weight loss treatments may offer for people who are struggling with obesity and the associated health impacts. Private medical insurance generally covers unexpected illnesses and conditions that are likely to respond quickly to treatment rather than illnesses and conditions that could last a long time.”
Bupa does offer a plan that combines weight loss drugs with a structured lifestyle programme. It includes a GP consultation to assess BMI, medical history and weight-related conditions as well as coaching, nutrition, exercise plans and ongoing clinical oversight. Bupa also offers access to a nurse helpline and a follow-up GP review after six months.
Vitality also sees weight as sitting within a preventative approach, embedding weight management within its wider wellbeing programme. Last year it added a medicated pathway featuring GLP-1s, citing growing evidence of their potential to reduce physical health complications and support a wider shift towards healthier lifestyles.
The medicated pathway is available to members with a BMI of 35 or above and a weight-related condition, while non-medicated support is offered to those with a BMI of 30 or above, or 25 and above with type 2 diabetes.
Bupa’s plan can be fully or partially employer-funded, for those employers comfortable with taking on board an expense that could run for years, or offered as an employee-paid benefit. It operates separately from standard PMI, so standard corporate health premiums are not directly affected. Vitality’s pathway is embedded within its broader wellbeing programme rather than standard corporate health cover, meaning PMI premiums are not impacted, with costs generally absorbed through the programme or employer contribution.
Clinical impact
Insurers that offer GLP-1 access tend to frame the business case around long-term health improvements, workforce resilience and reduced claims rather than the medication alone.
Bupa emphasises reductions in productivity loss and employee absence due to weight-related conditions. Bupa UK head of corporate product Paula Dermody adds that supporting weight management helps “reduce
the risk of serious long-term health conditions and build healthier habits for the future in a way that’s manageable, supporting lasting wellbeing and workforce resilience.”
VitalityHealth data shows that people with obesity are 35 per cent more likely to be hospitalised for any condition, 70 per cent more likely for musculoskeletal issues, and 123 per cent more likely for cardiac conditions. The use of weight loss drugs is linked to a 33 per cent reduction in hospital costs, rising to 63 per cent with moderate exercise, highlighting the benefits of combining medication with behaviour change.
Vitality deputy CEO Dr Katie Tryon says: “Weight loss can be life-changing, significantly reducing health risks and supporting a broader shift towards healthier, more sustainable lifestyles.”
Employers are also examining obesity through the lens of clinical risk and workforce outcomes. Aviva medical director Dr Suba M says: “The focus tends to be on the potential role of weight-loss medicines in controlling wider clinical risks associated with obesity, such as diabetes,
cardiovascular risk and other comorbidities – from a clinical risk-reduction perspective rather than general wellbeing or productivity.”
Employer demand
Prevention of medical conditions is becoming a bigger focus in boardrooms, even if funding hasn’t always been there to pay for it. Advisers report more employer questions about weight loss drugs, including how they would be offered, what governance would be required and whether they would fall under private medical insurance.
Everywhen head of wellbeing Debra Clarke says: “Historically, employers may have felt that weight loss and weight-loss drugs were not an area to get involved in for their employees but the landscape seems to be changing. More employees now expect their employers to support their wider health and wellbeing journey, and this seems to include weight issues.”
Dermody notes that employers are increasingly looking for preventative solutions to help their people stay well and in work. But some insurers remain cautious due to limited employer demand and the challenges of covering chronic, high-cost treatments within an acute-focused insurance model.
Aviva reports little demand from corporate clients for this type of cover, but says it continues to monitor emerging evidence and guidance. Dr M notes: “Some employers felt it would be unfair to fund a benefit only some employees would use, while others viewed the cost as prohibitive. From our experience, building a business case for funding weight-loss medications isn’t a priority for employers.”
Clarke suggests that employers can still support employees without providing medication, by raising awareness about the many benefits of maintaining a healthy weight and sharing guidance based on behaviour change principles.
Governance and risk
Managing weight-loss medications requires a multi-disciplinary approach combining medication with lifestyle and behavioural support. But this can be challenging for private healthcare frameworks which are designed primarily for short-term, acute conditions rather than chronic diseases such as obesity.
Clarke notes: “As we are so early in fully understanding the impact weight-loss drugs can have longer term, it is reassuring that the providers who are supporting this are doing so with wrap around support and guidance.”
Bupa’s programme integrates governance with prescribed medication, lifestyle support, and ongoing GP oversight, providing guidance on use, side effects and safe discontinuation. Similarly, VitalityHealth provides access through clinical partners to help individuals develop lasting healthy habits with evidence-based lifestyle coaching covering both physical and mental health.
Dr M adds that the safe and effective use of weight loss drugs requires a comprehensive model of care, including ongoing clinical monitoring, nutritional and behavioural support and psychological input. She says: “Such integrated services are more readily delivered through NHS-commissioned pathways, not easily replicated within a private health cover framework.”
Employers considering weight loss drug access must balance cost, eligibility and the proportion of the workforce likely to benefit. There is limited long-term evidence on weight-loss durability, and a recent BMJ analysis found that although patients lose weight during treatment, regain is common once the medication is stopped.
Additionally, equity is a key consideration because not every employee will actually need or benefit from these medicines.
Dr M says: “Their high cost combined with clinical evidence that weight regain often occurs once treatment stops means employers must think carefully about how they are offered. Communication must also be handled with sensitivity. Employees should feel informed, supported and not pressured when considering options.”
Private healthcare frameworks may limit the ability to deliver integrated care. Dr Hasan explains that while weight-loss treatments offer potential benefits, “there is still more to discover about how to best use weight loss injections to ensure effective, sustainable, and healthy long-term weight loss,” and notes obesity treatment is not currently covered under private medical insurance.
Employers and insurers will need to decide the extent to which weight loss drugs should remain outside corporate healthcare or form part of a wider prevention strategy. The long-term effects of these drugs on individuals are still emerging and careful consideration is needed around who would benefit and how support could be provided. Meanwhile, insurers are exploring ways to offer integrated care that combines medication with lifestyle guidance and ongoing clinical oversight, but for now the sector is still defining where these boundaries lie.
